Tess Schmalbach

544 total citations
24 papers, 446 citations indexed

About

Tess Schmalbach is a scholar working on Immunology, Oncology and Epidemiology. According to data from OpenAlex, Tess Schmalbach has authored 24 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 10 papers in Oncology and 5 papers in Epidemiology. Recurrent topics in Tess Schmalbach's work include Immunotherapy and Immune Responses (9 papers), Immune Response and Inflammation (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Tess Schmalbach is often cited by papers focused on Immunotherapy and Immune Responses (9 papers), Immune Response and Inflammation (4 papers) and Radiopharmaceutical Chemistry and Applications (3 papers). Tess Schmalbach collaborates with scholars based in United States, Germany and United Kingdom. Tess Schmalbach's co-authors include Lynda C. Schneider, William R. Lumry, Mohammed Al-Adhami, Rosana Kapeller, H. James Harwood, Geraldine Harriman, William Westlin, Heather H. Kelley, Carine Beysen and Wenyan Miao and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Hepatology.

In The Last Decade

Tess Schmalbach

23 papers receiving 426 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tess Schmalbach United States	10	148	128	114	99	99	24	446
Jane Birtwistle United Kingdom	12	127 0.9×	102 0.8×	209 1.8×	28 0.3×	65 0.7×	21	554
Gillian McNab United Kingdom	10	235 1.6×	97 0.8×	187 1.6×	25 0.3×	135 1.4×	11	620
Janina Suchy Poland	19	104 0.7×	78 0.6×	299 2.6×	36 0.4×	324 3.3×	42	807
Thomas A. Zanardi United States	10	115 0.8×	42 0.3×	286 2.5×	52 0.5×	32 0.3×	13	492
Ayşe Özer Türkiye	14	23 0.2×	92 0.7×	225 2.0×	95 1.0×	152 1.5×	31	538
Yun Zhuang China	14	113 0.8×	112 0.9×	146 1.3×	72 0.7×	71 0.7×	31	440
K Takeyama Japan	12	65 0.4×	61 0.5×	194 1.7×	138 1.4×	217 2.2×	32	636
Toshifumi Hoki Japan	7	147 1.0×	87 0.7×	92 0.8×	20 0.2×	180 1.8×	21	381
Yoji Miyamoto Japan	7	40 0.3×	149 1.2×	232 2.0×	38 0.4×	74 0.7×	15	560
Maria Radanova Bulgaria	12	199 1.3×	32 0.3×	122 1.1×	25 0.3×	45 0.5×	36	424

Countries citing papers authored by Tess Schmalbach

Since Specialization

Citations

This map shows the geographic impact of Tess Schmalbach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tess Schmalbach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tess Schmalbach more than expected).

Fields of papers citing papers by Tess Schmalbach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tess Schmalbach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tess Schmalbach. The network helps show where Tess Schmalbach may publish in the future.

Co-authorship network of co-authors of Tess Schmalbach

This figure shows the co-authorship network connecting the top 25 collaborators of Tess Schmalbach. A scholar is included among the top collaborators of Tess Schmalbach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tess Schmalbach. Tess Schmalbach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Papadopoulos, Kyriakos P., Justin C. Moser, Jordi Rodón, et al.. (2024). 676 Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies. Regular and Young Investigator Award Abstracts. A775–A775. 2 indexed citations

2.

Singh, Dave, Arjun Ravi, Katie Kane, Tess Schmalbach, & David L. Hava. (2018). The pharmacokinetics, pharmacodynamics and tolerability of PUR0200, a novel tiotropium formulation, in chronic obstructive pulmonary disease. British Journal of Clinical Pharmacology. 84(9). 2097–2105. 9 indexed citations

3.

Westlin, William, Geraldine Harriman, H. James Harwood, et al.. (2016). NDI-010976, a Potent, Liver-Directed, Oral Inhibitor of Acetyl Coa Carboxylase for Non-Alcoholic Steatohepatitis: Pharmacodynamic Effects on Hepatic De Novo Lipogenesis in Obese but Otherwise Healthy Adult Male Volunteers. Journal of Hepatology. 64(2). S190–S191. 4 indexed citations

4.

Richards, Donald, Joe Stephenson, Brian M. Wolpin, et al.. (2012). A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology. 30(4_suppl). 213–213. 34 indexed citations

5.

Stephenson, John, Donald Richards, Brian M. Wolpin, et al.. (2011). The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer.. Journal of Clinical Oncology. 29(15_suppl). 4114–4114. 30 indexed citations

6.

Senzer, Neil, David S. Mendelson, Colin D. Weekes, et al.. (2011). Abstract B101: Safety, tolerability, and pharmacokinetics of IPI-493, an oral Hsp90 inhibitor, in patients with advanced cancers.. Molecular Cancer Therapeutics. 10(11_Supplement). B101–B101. 2 indexed citations

7.

Schneider, Lynda C., et al.. (2007). Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor. Journal of Allergy and Clinical Immunology. 120(2). 416–422. 104 indexed citations

8.

Vicari, Alain, Tess Schmalbach, Julie Lekstrom-Himes, et al.. (2007). Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.. PubMed. 12(5). 741–51. 33 indexed citations

9.

Levy, Robyn J., et al.. (2007). Interim Open-Label Results of EDEMA3sm: A Study of Subcutaneous Ecallantide in Patients with Hereditary Angioedema. Journal of Allergy and Clinical Immunology. 119(1). S276–S276. 3 indexed citations

10.

Vicari, Alain, Tess Schmalbach, Julie Lekstrom-Himes, et al.. (2007). Safety, Pharmacokinetics and Immune Effects in Normal Volunteers of CPG 10101 (ACTILON™), an Investigational Synthetic Toll-like Receptor 9 Agonist. Antiviral Therapy. 12(5). 741–751. 33 indexed citations

11.

Manegold, C., et al.. (2005). Combination of a Toll-like receptor 9 (TLR9) agonist, CPG 7909 (CPG) with first line taxane/platinum improves response rate in late stage non-small-cell lung cancer (NSCLC). mediaTUM (Technical University of Munich). 2 indexed citations

12.

Gravenor, Donald, Donald Woytowitz, J. Mezger, et al.. (2005). CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study. Journal of Clinical Oncology. 23(16_suppl). 7039–7039. 17 indexed citations

13.

Wagner, Stephan N., Jeffrey S. Weber, Bruce G. Redman, et al.. (2005). CPG 7909, a TLR9 agonist immunomodulator in metastatic melanoma: A randomized phase II trial comparing two doses and in combination with DTIC. Journal of Clinical Oncology. 23(16_suppl). 7526–7526. 12 indexed citations

14.

Manegold, C., Donald Gravenor, Donald Woytowitz, et al.. (2005). PD-046 Phase II randomized trial adding a toll-like receptor 9 agonist (ProMuneTM) to first line chemotherapy shows improved response in advanced non-small cell lung cancer. Lung Cancer. 49. S79–S80. 1 indexed citations

15.

Kim, Hyun Soo, Michael Girardi, Timothy M. Kuzel, et al.. (2004). TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909.. Blood. 104(11). 743–743. 9 indexed citations

16.

Kim, Yunho, et al.. (2004). Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CPG immunomodulator (CPG 7909), a phase I study. Journal of Clinical Oncology. 22(14_suppl). 6600–6600. 6 indexed citations

17.

Weiner, George J., et al.. (2004). Combination of CpG7909 and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): A phase I, open label dose-escalation study of safety and tolerability. Journal of Clinical Oncology. 22(14_suppl). 6594–6594. 5 indexed citations

18.

Kuzel, Timothy M., et al.. (2004). Phase Ib trial of a targeted TLR9 CpG immunomodulator (CPG 7909) in advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 22(14_suppl). 4644–4644. 20 indexed citations

19.

Weiner, George J., et al.. (2004). Combination of CpG7909 and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): A phase I, open label dose-escalation study of safety and tolerability. Journal of Clinical Oncology. 22(14_suppl). 6594–6594. 1 indexed citations

20.

Gravenor, Donald, et al.. (2004). A TLR9 CpG immunomodulator in combination with chemotherapy as treatment for advanced non-small cell lung cancer (NSCLS), a randomized, controlled phase II study. Journal of Clinical Oncology. 22(14_suppl). 7126–7126. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact